medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2014, Number 1

<< Back Next >>

Rev Esp Med Quir 2014; 19 (1)

Concentrations of glycosylated haemoglobin A1c in different treatments for diabetes

Angulo PEE, Félix LRM, Félix LAR, Hernández ML, Martínez VKG

Language: Spanish
References: 18
Page: 17-22
PDF size: 503.71 Kb.


ABSTRACT

Background: Diabetes is a chronic degenerative disease that represents a public health problem, occurring in 10% of the population in Mexico.
The laboratory test of glycosylated hemoglobin (A1c) is used to know how well diabetes is controlled. The aim of the study was to determine the level of hemoglobin A1c in the treatment of the diabetic patient attending to ISSSTE hospital.
Material and methods: We performed a prospective descriptive survey. Sample: diabetic patients attending to the laboratory of the Regional Hospital. Glycosylated hemoglobin was measured: a level of 2.5 to 5.9% indicated good control, adequate control 6-8 and ≥ 8 poor control treatment. Additional variables were: gender, age, type of diabetes, type of treatment, occupation. Statistical analysis: mean and standard deviation, t student and Chi-square, 95% confidence intervals were done with significance level ‹ 0.05.
Results: We studied 86 patients, male 29 (33.7%) and 57 female (66.3%), age 57.6 ± 12.2 years old. The mean Hb A1c was 8.03 ± 2.2. The level of Hb A1c with good control was 45 (52.3%), poorly controlled 37 (43%), and 4 (4.7%) controlled. Glycosylated hemoglobin A1c level by specialty and type of treatment for diabetes had no significant difference (p › 0.05). Hb A1c level by the frequency of the type of diabetes and gender, had significant differences (p ‹ 0.05).
Conclusions: We recommended developing clinical guidelines based on evidence for the treatment of diabetes, as well as educational strategies for adherence to treatment.


REFERENCES

  1. Kumate Rodríguez J. Atlas de la Salud. 1.ª Impresión 1993:39.

  2. World Health Organization, Department of Noncommunicable Disease Surveillance. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva: WHO; 1999.

  3. Alemzadeh R, Ali O. Diabetes Mellitus. En: Kliegman RM, ed. Kliegman: Nelson Textbook of Pediatrics. 19th ed. Philadelphia, Pa: Saunders, 2011:583.

  4. American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2010;34(Suppl 1):S11- S61.

  5. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694- 2701.

  6. Harrison. Principios de Medicina Interna 16a edición (2006). Capítulo 338. Diabetes mellitus» (en español). Harrison online en español. McGraw-Hill. Consultado el 22 de julio de 2009.

  7. Eisenbarth GS, Polonsky KS, Buse JB. Type 1 Diabetes Mellitus. En: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Kronenberg: Williams Textbook of Endocrinology. 11th ed. Philadelphia, Pa: Saunders Elsevier, 2008.

  8. In the clinic. Type 2 diabetes. Ann Intern Med 2007;146:ITC- 1-ITC-15.

  9. American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011;34(Suppl 1):S11-61.

  10. Eisenbarth GS, Polonsky KS, Buse JB. Type 1 Diabetes Mellitus. En: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Kronenberg: Williams Textbook of Endocrinology. 11th ed. Philadelphia, Pa: Saunders Elsevier, 2008:31.

  11. World Health Organization, Department of Noncommunicable Disease Surveillance. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.” Geneva: WHO; 1999.

  12. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statementof the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694-701.

  13. World Health Organization, Department of Noncommunicable Disease Surveillance. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.” Geneva: WHO; 1999.

  14. Miguel Ángel Lezana Fernández, Carlos Humberto Álvarez Lucas, Edith Milena Álvarez Martínez, Alicia Velázquez, Gabriela Ortiz Solís, Guadalupe Yazmín Dávila Lara, Agustín Lara Esqueda. Hemoglobina glucosilada en 1,152 sujetos con diabetes, que participaron en la estrategia UneMes recorridos por la Salud en México en 2009. Med Int Mex 2010;26:337-345.

  15. Ana Leticia Ramos Domínguez, Guadalupe Rojas Zarate, Francico Solís Páez. Evaluación de hemoglobina glicosilada en pacientes diabéticos del Centro de Salud de Teocelo Veracruz. Rev Med 2008;8:11-13.

  16. Villarreal-Ríos E, Paredes Chaparro A, Martínez-González L, Galicia-Rodríguez L, Vargas-Daza E, Garza-Elizondo ME. Control de los pacientes con diabetes tratados sólo con esquema farmacológico. Rev Med Inst Mex Seguro Soc 2006;44:303-308.

  17. Jiménez-Navarrete Manuel, Ruiz-Pérez Leonor. Niveles de glicemia y de hemoglobina glicosilada en un grupo de pacientes diabéticos tipo II de la Península de Guanacaste, Costa Rica. Rev Costarric Cienc Méd 2002;23:133-144.

  18. Adriana Laclé-Murray, Manuel Francisco Jiménez-Navarrete. Calidad del control glicémico según la hemoglobina glucosilada vs la glicemia en ayunas: Análisis en una población urbana y otra rural de diabéticos costarricenses. AMC 2004;46:139-144.




2020     |     www.medigraphic.com